Modality
Bispecific Ab
MOA
PLK4i
Target
PSMA
Pathway
Lipid Met
Prostate Ca
Development Pipeline
Preclinical
~Feb 2019
→ ~May 2020
Phase 1
~Aug 2020
→ ~Nov 2021
Phase 2
Feb 2022
→ May 2030
Phase 2Current
NCT04289981
1,899 pts·Prostate Ca
2022-02→2030-05·Recruiting
1,899 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-05-224.1y awayPh2 Data· Prostate Ca
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2
Recruit…
Catalysts
Ph2 Data
2030-05-22 · 4.1y away
Prostate Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04289981 | Phase 2 | Prostate Ca | Recruiting | 1899 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Doxacagene | Sanofi | Approved | PSMA | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| BGN-3859 | BeiGene | Approved | PSMA | |
| DAW-8159 | Day One Bio | Phase 2 | PSMA | |
| Liravorutinib | Biomea Fusion | Phase 1/2 | GPRC5D |